British Journal of Cancer

Article	Citations
Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells	264
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC	248
Reply to Comment on: ‘Hypoxia differently modulates the release of mitochondrial and nuclear DNA’	153
Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial	133
Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours	132
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach	121
Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma	112
Patterns of incident Burkitt lymphoma during the HIV epidemic among the Black African and White population in South Africa	111
Treating tobacco dependency in cancer care: essential, cost-effective, and feasible, yet overlooked	109
Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom	107
GDP-bound Rab37 modulates M2-like tumor-associated macrophage polarization by attenuating STAT1 translocation to downregulate the type I IFN pathway	107
CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer	101
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts	99
Effects of cancer screening restart strategies after COVID-19 disruption	98
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer	94
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	91
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	89
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	85
An emerging role for BAG3 in gynaecological malignancies	81
C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer	81
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer	81
Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo	80
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	79
Statin use and survival among women with ovarian cancer: an Australian national data-linkage study	74
Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database	72

Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia	71
Advancing translational research for colorectal immuno-oncology	71
Liquid biopsy: creating opportunities in brain space	70
A spectroscopic liquid biopsy for the earlier detection of multiple cancer types	70
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	65
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	65
Correction: Maternal and childhood medical history and the risk of childhood brain tumours: a case–control study in Ontario, Canada	64
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies	64
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy	62
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases	62
Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma	62
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	62
A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study	61
Clinical impact of PET/MRI in oligometastatic colorectal cancer	61
Correction: How do women experience a false-positive test result from breast screening? A systematic review and thematic synthesis of qualitative studies	61
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	61
Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence	60
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience	59
Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80	58
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	58
A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer	56
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	56
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	55
The cost-effectiveness of risk-stratified breast cancer screening in the UK	55
Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme	55
A taxonomy of early diagnosis research to guide study design and funding prioritisation	55
Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women	54
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours	54
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit	53
SIRT1 is an actionable target to restore p53 function in HPV-associated cancer therapy	53
Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer	53
Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case–control study	53
Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer	52
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	51
Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy	51
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms	50
Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers	49
Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study	48
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies	47
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases	47
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade	46
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	46
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label,	46
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma	45
The use of biomarkers and HPV genotyping to improve diagnostic accuracy in women with a transformation zone type 3	45
Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study	45
Associations of diabetes, circulating protein biomarkers, and risk of pancreatic cancer	45
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis	45
Minimum latency effects for cancer associated with exposures to radiation or other carcinogens	45
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	45

Association between weight cycling and risk of colorectal cancer: a prospective cohort study	43
Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas	43
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy	43
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England	42
TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors	42
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma	42
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer	41
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours	41
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer	41
Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank	40
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients	40
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis	40
The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients	40
Socio-economic inequalities in cancer survival: how do they translate into Number of Life-Years Lost?	39
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer	39
Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset	39
Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	39
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	39
Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test	39
Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study	39
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	39
A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform	38
wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning	38
Non-coding RNAs as liquid biopsy biomarkers in cancer	38
Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours	38
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	38
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	37
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	37
MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer	37
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting	37
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery	37
Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation	37
Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy	37
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity	37
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity	36
Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort	36
Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis	36
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer	36
A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation a	35
A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp	35
Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab	35
Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma	35
Long-term exposure to ambient air pollution and bladder cancer incidence in a pooled European cohort: the ELAPSE project	35
Intratumoural haematopoietic stem and progenitor cell differentiation into M2 macrophages facilitates the regrowth of solid tumours after radiation therapy	34
Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence	34
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	34
Comment on “Redefining cancer research for therapeutic breakthroughs”	34
Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic effic	33
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications	33
Comments on “Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer”	32
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer	32
RE: Reply to Rio-Vilariño and colleagues’ article and misconception about YAP1 Ser 397 phosphorylation function	32
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer	32
Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms	32
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	32
Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway	32
Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy	31
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients	31
Correction: Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases	31
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study	31
Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium	31
A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis	31
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer	31
Metabolic adaptations in prostate cancer	31
CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway	31
The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)	30
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses	30
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling	30
Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation	30
Circulating tumour DNA: a challenging innovation to develop “precision onco-surgery” in pancreatic adenocarcinoma	30
Navigating therapeutic strategies: HPV classification in head and neck cancer	30
Metastasis-associated fibroblasts in peritoneal surface malignancies	30
The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer	29
Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study	29
Anti-PEc: Development of a novel monoclonal antibody against prostate cancer	29
Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines	29
Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging	29
Risk of cancer following primary care presentation with fatigue: a population-based cohort study of a quarter of a million patients	29
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?	29
SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling	28

Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells	28
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	28
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade	28
Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer	28
PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM	28
Biomarkers of response to PD-1 pathway blockade	28
Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression	28
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them	28
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice	27
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing	27
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour	27
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	27
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	27
Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)	27
What kind of tumour rupture requires adjuvant therapy?	27
Biomarker testing in cancer management- can one size fit all?	27
Predicted leukocyte telomere length and risk of germ cell tumours	27
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study	27
Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data	27
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma	27
TGFβ carrying exosomes in plasma: potential biomarkers of cancer progression in patients with head and neck squamous cell carcinoma	26
An old friend with a new face: tRNA-derived small RNAs with big regulatory potential in cancer biology	26
Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma	26
Th2 cells inhibit growth of colon and pancreas cancers by promoting anti-tumorigenic responses from macrophages and eosinophils	26
Use the term “infiltrative” instead of “replacement” when defining histopathological growth pattern in patients with liver cancer	26
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development	26
Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic	26
Alternative methods to measure breast density in younger women	26
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges	26
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	26
Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer	26
A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer	26
Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666	26
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	26
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10	26
Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study	26
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	25
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome	25
Revitalising cancer clinical trials: definitely time for patient-centred reform	25
Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens	25
Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients	25
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	25
Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer	25
Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours	25
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	24
Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis	24
CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer	24
The dark side of synaptic proteins in tumours	24
Correction: Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	24
Genomic ALK alterations in primary and relapsed neuroblastoma	24
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	24
Circulating tumour cells in gastrointestinal cancers: food for thought?	24
Patient attrition in Molecular Tumour Boards: a systematic review	24
Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guérin therapy	24
Crucial immunological roles of the invasion front in innate and adaptive immunity in cervical cancer	24
Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age	24
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer	24
Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer	24
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	24
HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial	24
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase	24
Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer	23
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306	23
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	23
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	23
Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer	23
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	23
Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	23
Genomic landscape of pleural and peritoneal mesothelioma tumours	23
BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial	23
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations	23
AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene	23
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	23
A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis	23
Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis	23
Cancer care for migrant people	23
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	22
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	22
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma	22
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	22
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	22
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	22
Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Co	22
Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas	22
Advancing radiomics from contrast-enhanced mammography in breast cancer	22
The role of PPARγ in prostate cancer development and progression	22
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules	22
Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer	22
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer	22
Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy	22
Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect	22
The tumour immune microenvironment in oesophageal cancer	21
Proteogenomics drives therapeutic hypothesis generation for precision oncology	21
The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients	21
Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway	21